For Ada Health Patient Finder Business Development
Report Date: March 11, 2026
Prepared by: Ada Cockpit Research Team
Johnson & Johnson (NYSE: JNJ) is a global healthcare conglomerate headquartered in New Brunswick, New Jersey, founded in 1886. With approximately 135,000-140,000 employees worldwide, J&J operates through two primary segments: Innovative Medicine (pharmaceuticals, $60.4B in 2025) and MedTech (medical devices, ~$33.8B in 2025).
Market Capitalization: $580.18 billion (March 11, 2026)
Stock Price: $243.71 (March 10, 2026 close)
2026 Guidance: $99.5-100.5 billion revenue
Johnson & Johnson stands as the world's largest and most diversified healthcare company, ranking #2 among pharmaceutical firms by market capitalization ($580B). The company has successfully pivoted from its legacy consumer products business toward high-growth innovative medicines and medical technology, with oncology emerging as the primary growth engine ($25.4B in 2025, +21.9% operational growth).
| Product | Revenue (2025) | Growth YoY | Key Indication | Status |
|---|---|---|---|---|
| DARZALEX | $14.4B+ | +22-23% | Multiple Myeloma | Market leader, all lines of therapy |
| STELARA | ~$5.4B (est.) | -48% Q4 | Psoriasis, IBD | Biosimilar erosion underway |
| TREMFYA | $5B+ | +75% Q4 | Psoriasis, PsA, IBD | Successor to STELARA |
| IMBRUVICA | ~$2.7B (2023) | -20-22% | CLL, Lymphomas | Declining (competition, CMS cuts) |
| CARVYKTI | ~$2.2B (est.) | +66% Q4 | Multiple Myeloma (CAR-T) | High growth, post-1L approval |
Ada Health's Patient Finder business model can generate $645 million to $1.2 billion in annual value across J&J's portfolio by identifying undiagnosed patients and navigating them to therapy. The following drugs represent the highest-fit opportunities:
| Annual Addressable Patients | 100,000-200,000 |
| Net Revenue per Patient (Year 1) | $13,000-18,000 |
| Ada Patient Finder Value (10% fee) | $155-310 million annually |
| Key Rationale | 30-55% of depression patients have treatment-resistant depression (TRD), but only 66.7% receive evidence-based treatment. 2.5 million undertreated TRD patients exist in the U.S. Ada's mental health symptom assessment can identify patients cycling through failed antidepressants and navigate them to SPRAVATO-certified clinics. |
| Diagnostic Challenge | Only 5-7% of primary care depression patients achieve remission. TRD patients often remain in primary care without psychiatry referral or knowledge of advanced options like SPRAVATO. |
| Annual Addressable Patients | 50,000-80,000 |
| Net Revenue per Patient (Year 1) | $25,000-35,000 |
| Ada Patient Finder Value (10% fee) | $150-240 million annually |
| Key Rationale | 9-15.5% of psoriatic arthritis (PsA) patients are undiagnosed (202,500-348,750 total undiagnosed in U.S.). Median diagnostic delay is 10.8 months, with >50% delayed >2 years. Physician delay (4.5 months) significantly exceeds patient delay (1.0 month), indicating systemic diagnostic failure. Ada can surface joint pain, stiffness, dactylitis (sausage fingers), and enthesitis (heel pain) to prompt rheumatology referral. |
| Annual Addressable Patients | 40,000-60,000 |
| Net Revenue per Patient (Year 1) | $25,000-35,000 |
| Ada Patient Finder Value (10% fee) | $120-180 million annually |
| Key Rationale | Nearly 50% of IBD patients experience diagnostic delays exceeding clinical thresholds (>6 months for ulcerative colitis, >12 months for Crohn's disease). 320,000-350,000 moderate-to-severe IBD patients in diagnostic limbo. Ada can distinguish IBD from IBS via symptom patterns (bloody diarrhea, nocturnal urgency, weight loss, extraintestinal symptoms) and prompt immediate GI referral and colonoscopy. |
| Annual Addressable Patients | 10,000-15,000 |
| Net Revenue per Patient (Year 1) | $70,000-100,000 |
| Ada Patient Finder Value (10% fee) | $85-127 million annually |
| Key Rationale | 50% of multiple myeloma patients experience diagnostic delays >3 months, with average 6-11 months from symptom onset to diagnosis. 17,500 delayed diagnoses per year in U.S. (out of ~35,000 new cases). Symptoms—bone pain (especially back), fatigue, recurrent infections, anemia, kidney dysfunction—are surfaceable via Ada's clinical assessment. High per-patient value offsets rarity. |
| Annual Addressable Patients | 3,000-6,000 |
| Net Revenue per Patient (Year 1) | $110,000-160,000 |
| Ada Patient Finder Value (10% fee) | $40-81 million annually |
| Key Rationale | Median 8-12 month diagnostic delay for generalized myasthenia gravis (gMG); 10,000-15,000 undiagnosed in U.S. The hallmark pattern—"muscle weakness worsening with use" (ptosis worsening in afternoon, diplopia after reading, dysphagia mid-meal)—is pathognomonic and surfaceable via Ada. Simple confirmatory blood test (anti-AChR antibodies) available. High per-patient value justifies rare disease targeting. |
| Company | 2024/2025 Revenue | Market Cap | Key Competing Assets |
|---|---|---|---|
| Johnson & Johnson | $94.2B | $580B | DARZALEX, TREMFYA, ERLEADA |
| AbbVie | $56.3B | $401B | Skyrizi, Rinvoq, Imbruvica (co-marketed) |
| Roche | $49.9B | ~$250B | Oncology portfolio (Tecentriq, Avastin, Herceptin) |
| Merck & Co. | $53.6B | ~$290B | Keytruda (immuno-oncology leader), Gardasil |
| Bristol Myers Squibb | $45-48B | $122B | Revlimid (post-LOE), Opdivo, Eliquis, Abecma |
J&J has provided 2026 revenue guidance of $99.5-100.5 billion (operational sales), reflecting 5.7-6.7% growth from 2025 levels and exceeding Wall Street consensus of $98.9 billion. Adjusted EPS is guided at $11.4-11.6, representing 5-7% profit growth.
The company projects:
| Valuation Metric | Value (March 2026) | Notes |
|---|---|---|
| Stock Price | $243.71 | March 10, 2026 close |
| Market Capitalization | $580.18B | #2 pharma by market cap |
| P/E Ratio (trailing) | ~22.1x | Based on 2025 EPS of $11.03 |
| P/E Ratio (forward) | ~21.0x | Based on 2026 guidance $11.53 midpoint |
| Dividend Yield | ~3.0% | Dividend Aristocrat (62 consecutive years) |
| Region | Revenue | % of Total | YoY Growth |
|---|---|---|---|
| United States | $53.75B | 57.1% | 6.9% |
| Europe | $21.54B | 22.9% | ~5% (est.) |
| Asia Pacific & Africa | $14.03B | 14.9% | ~4-6% (est.) |
| Western Hemisphere (ex-U.S.) | $4.88B | 5.2% | ~4-6% (est.) |
| Total Worldwide | $94.19B | 100% | 6.1% |
| Name | Title | Scope |
|---|---|---|
| Joaquin Duato | Chairman & CEO | Overall company P&L; became CEO Jan 3, 2022 |
| Jennifer L. Taubert | EVP, Worldwide Chairman, Innovative Medicine | $60.4B Innovative Medicine segment; Fortune MPW 2022-2025 |
| Tim Schmid | EVP, Worldwide Chairman, MedTech | ~$33.8B MedTech segment; robotics, orthopaedics, surgery |
| Joseph J. Wolk | EVP & Chief Financial Officer | Financial operations; CFO since 2018; Prudential & Stanford Medicine boards |
J&J invested approximately $14.7 billion in R&D in 2025 (19.4% of sales in 2024), maintaining one of the industry's largest pipelines with 15+ Phase 3 programs.
| Asset | Indication | Phase | Expected Milestone |
|---|---|---|---|
| Nipocalimab (IMAAVY) | CIDP, Lupus, Warm AIHA | Phase 3 | Filings 2025-2026 |
| TAR-200 (INLEXZO) | Non-muscle invasive bladder cancer | Phase 3 | SunRISe-3, SunRISe-5 trials ongoing |
| Icotrokinra (Icotide) | Psoriasis, IBD | Phase 2/3 | First approvals expected 2026-27 |
| Milvexian | Stroke prevention (anticoagulant) | Phase 3 | Data ~2025, filing ~2026 |
| OTTAVA Surgical System | General surgery robotics | IDE / Pre-commercial | Launch 2026-2027 |
| MONARCH Platform | Urology robotics | Development | Launch 2026-2027 |
Johnson & Johnson's portfolio presents exceptional opportunities for Ada Health's Patient Finder business, with an estimated $645 million to $1.2 billion in annual value across seven high-fit drugs:
The Patient Finder model aligns perfectly with J&J's strategic priorities: accelerating oncology growth (DARZALEX), offsetting STELARA biosimilar erosion (TREMFYA), and establishing neuroscience leadership (SPRAVATO). By identifying undiagnosed patients and navigating them to therapy earlier, Ada Health enables true market expansion—finding patients the healthcare system misses—while simultaneously improving clinical outcomes through earlier intervention.
This is not marketing spend. This is market expansion through better diagnosis.